ESSA Pharma
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.
Realm Therapeutics
Acquisition in 2019
Realm Therapeutics is a biopharmaceutical company based in Malvern, Pennsylvania, focused on leveraging proprietary technologies to enhance health outcomes for adults and children. Initially established to develop therapies for immune-mediated diseases, the company is currently seeking opportunities to invest in, partner with, or acquire entities with potential in the life sciences sector. Realm Therapeutics aims to develop small molecule therapies targeting inflammatory diseases, with applications in dermatology and ophthalmology, as well as potential uses in other medical areas. Founded in 2016 and formerly known as PuriCore plc, Realm Therapeutics has limited operations and is a subsidiary of ESSA Pharma Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.